Diana Ernst, RPh

Editorial Director https://www.hematologyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Anemia

New Oral Therapy Approved for Iron Deficiency in Adults

Diana Ernst, RPh

July 30, 2019

The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.

Myeloma

Darzalex Gets Approval for Additional Multiple Myeloma Indication

Diana Ernst, RPh

June 28, 2019

The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Bleeding Disorders

Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation

Diana Ernst, RPh

April 10, 2019

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.

Myeloma

FDA Approves New Administration Option for Darzalex

Diana Ernst, RPh

February 19, 2019

The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.

Bleeding Disorders

FDA Approves Updated Labeling for Hemophilia A Treatment Novoeight

Diana Ernst, RPh

December 7, 2018

The indication has been changed from “control and prevention of bleeding episodes” to “on-demand treatment and control of bleeding episodes” in adults and children with hemophilia A.

Bleeding Disorders

Amicar Tablet Generic Gets FDA Approval

Diana Ernst, RPh

December 3, 2018

Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.

Anemia

New Tablet Strength of Sickle Cell Anemia Treatment Siklos Available

Diana Ernst, RPh

November 20, 2018

In addition to the 1000mg tablet, Siklos is also available in 100mg tablets.

Anemia

Promacta Approved as First-Line Treatment for Severe Aplastic Anemia

Diana Ernst, RPh

November 19, 2018

The approval was based on data from a single-arm, open-label sequential cohort study in which patients received Promacta in combination with horse antithymocyte globulin (h-ATG) and cyclosporine.

Lymphoma

Adcetris Plus Chemotherapy Approved for Peripheral T-Cell Lymphoma

Diana Ernst, RPh

November 16, 2018

The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.